Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX: Betrixaban vs Enoxaparin for VTE Prevention
NCT01583218Phase 3Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Mar 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 34
01
Overview
A Phase 3 trial of betrixaban in venous thromboembolism (VTE), sponsored by Portola Pharmaceuticals. Started Mar 2012; status: completed.
02
Drugs
betrixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01583218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01583218.